Quince Therapeutics Inc. (QNCX) is progressing with its Phase 3 NEAT trial of EryDex, an investigational drug/device combination for Ataxia-Telangiectasia (A-T), with enrollment expected to be completed in the second quarter of 2025. This milestone brings the company closer to potentially addressing a significant unmet need for patients with this rare neurodegenerative disease.
EryDex for Ataxia-Telangiectasia
A-T is an inherited autosomal recessive neurodegenerative and immunodeficiency disorder. Approximately 4,600 individuals in the U.S. have been diagnosed with A-T. Currently, there are limited treatment options available to address the neurological complications associated with the disease.
The NEAT trial is an international, multi-center, pivotal study designed to evaluate the neurological effects of EryDex in patients with A-T. Topline results from the trial are anticipated in the fourth quarter of 2025. Positive results could pave the way for regulatory approval and provide a much-needed therapy for this patient population.
Expansion into Duchenne Muscular Dystrophy
Beyond A-T, Quince Therapeutics is also exploring the potential of EryDex in treating Duchenne muscular dystrophy (DMD), a severe form of inherited muscular dystrophies. The company plans to initiate a Phase 2 trial in this indication in 2025. This expansion reflects the company's commitment to leveraging EryDex's mechanism of action to address other neuromuscular disorders.
Financial Position
As of September 30, 2024, Quince Therapeutics reported having $47.8 million in cash, cash equivalents, and short-term investments. This financial position is expected to support the ongoing clinical development programs for EryDex.
